- Home
- LIN vs AZN Comparison
LIN vs AZN Comparison
Compare LIN & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIN
- AZN
- Stock Information
- Founded
- LIN 1879
- AZN 1992
- Country
- LIN United Kingdom
- AZN United Kingdom
- Employees
- LIN N/A
- AZN N/A
- Industry
- LIN Major Chemicals
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- LIN Industrials
- AZN Health Care
- Exchange
- LIN Nasdaq
- AZN Nasdaq
- Market Cap
- LIN 226.2B
- AZN 234.5B
- IPO Year
- LIN N/A
- AZN 1993
- Fundamental
- Price
- LIN $448.57
- AZN $63.39
- Analyst Decision
- LIN Buy
- AZN Buy
- Analyst Count
- LIN 12
- AZN 9
- Target Price
- LIN $491.90
- AZN $88.80
- AVG Volume (30 Days)
- LIN 1.9M
- AZN 7.5M
- Earning Date
- LIN 10-31-2024
- AZN 11-12-2024
- Dividend Yield
- LIN 1.24%
- AZN 2.34%
- EPS Growth
- LIN 8.95
- AZN 9.79
- EPS
- LIN 13.18
- AZN 4.15
- Revenue
- LIN $33,025,000,000.00
- AZN $51,206,000,000.00
- Revenue This Year
- LIN $2.23
- AZN $17.69
- Revenue Next Year
- LIN $5.26
- AZN $7.95
- P/E Ratio
- LIN $34.04
- AZN $29.92
- Revenue Growth
- LIN 1.77
- AZN 13.81
- 52 Week Low
- LIN $396.07
- AZN $60.47
- 52 Week High
- LIN $487.49
- AZN $87.68
- Technical
- Relative Strength Index (RSI)
- LIN 31.94
- AZN 20.49
- Support Level
- LIN $450.86
- AZN $62.94
- Resistance Level
- LIN $457.87
- AZN $65.98
- Average True Range (ATR)
- LIN 5.81
- AZN 1.39
- MACD
- LIN -1.54
- AZN -0.35
- Stochastic Oscillator
- LIN 10.85
- AZN 5.68
About LIN Linde plc
Linde PLC is the industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $33 billion in revenue in 2023.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.